Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of “Moderate Buy” by Brokerages

Niagen Bioscience, Inc. (NASDAQ:NAGE) has earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $14.2750.

NAGE has been the subject of several recent analyst reports. Canaccord Genuity Group reduced their target price on shares of Niagen Bioscience from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd.

Insider Buying and Selling at Niagen Bioscience

In other news, CFO Ozan Pamir acquired 4,465 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were acquired at an average price of $6.81 per share, for a total transaction of $30,406.65. Following the completion of the purchase, the chief financial officer owned 7,372 shares in the company, valued at approximately $50,203.32. This trade represents a 153.59% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. 9.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Niagen Bioscience

Several institutional investors have recently added to or reduced their stakes in NAGE. Financial Consulate Inc. purchased a new position in shares of Niagen Bioscience in the third quarter worth about $33,000. Ameritas Investment Partners Inc. purchased a new position in Niagen Bioscience in the 3rd quarter valued at approximately $45,000. State of Alaska Department of Revenue bought a new stake in Niagen Bioscience during the 3rd quarter valued at $44,000. North Star Investment Management Corp. purchased a new stake in shares of Niagen Bioscience during the third quarter worth $47,000. Finally, Quantbot Technologies LP bought a new position in shares of Niagen Bioscience in the third quarter worth $48,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Trading Down 0.7%

NASDAQ:NAGE opened at $5.99 on Friday. The stock’s 50-day moving average is $6.48 and its 200-day moving average is $7.98. Niagen Bioscience has a 1-year low of $5.25 and a 1-year high of $14.69. The stock has a market cap of $478.06 million, a P/E ratio of 24.96 and a beta of 2.35.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Niagen Bioscience had a net margin of 16.38% and a return on equity of 24.13%. The firm had revenue of $33.99 million during the quarter, compared to the consensus estimate of $31.30 million.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.